MD Anderson Cancer Center
The University of Texas
Houston, TX
Accepting patients
QUINTESSENTIAL-2
A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Exposed Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
Accepting patients
QUINTESSENTIAL
A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
CA088-1005
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 1
- Has results